Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
Lewy Body Dementia Forecast in 12 Major Markets 2017-2027 Split by Gender and 5-Year Age Cohort

Dublin, March 27, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Lewy Body Dementia Forecast in 12 Major Markets 2017-2027" report to their offering. This report provides the current prevalent population for Lewy Body Dementia across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative dementia, accounting for approximately a third of all dementias. The presence of Lewy bodies in the brain is linked to low levels of important chemical messengers and the loss of connection between nerve cells. This leads to the progressive death of nerve cells and loss of brain tissue. Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Lewy Body Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for Lewy Body Dementia disease include:

  • Problems with alertness and attention, which fluctuate over the course of a day
  • Day-to-day memory problems
  • Visual hallucinations
  • Problems with motor control
  • Somatoform disorders
  • Issues organizing
  • Rapid eye movement sleep disorders
  • Problems with distance perception

Reasons to Buy

  • Able to quantify patient populations in global Lewy Body Dementia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Lewy Body Dementia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Lewy Body Dementia prevalent population.
  • Identify sub-populations within Lewy Body Dementia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Lewy Body Dementia patients.

Key Topics Covered:

  1. Introduction
  2. Cause of the Disease
  3. Risk Factors & Prevention
  4. Diagnosis of the Disease
  5. Variation by Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key comorbid conditions/Features associated with the disease
  8. Methodology for quantification of patient numbers
  9. Top-line prevalence for Lewy Body Dementia
  10. Clinical features of Lewy Body Dementia patients
  11. Symptoms of DLB patients
  12. Abbreviations used in the report
  13. Patient-Based Offering
  14. Online Pricing Data and Platforms
  15. References
  16. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/bhjxbw/lewy_body

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Central Nervous System Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 68

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 730

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 323

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 226

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
aria-label="Continue reading: JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer"> Continue Reading